COMPASS Pathways (NASDAQ: CMPS) is a mental healthcare company dedicated to accelerating patient access to evidence-based innovation in mental health, working to find better ways to help and empower people who are suffering with mental health challenges.

The company’s first major initiative is developing psilocybin therapy for treatment-resistant depression (TRD), for which program they received FDA Breakthrough Therapy designation in 2018. COMPASS is currently running the world’s first large-scale psilocybin therapy clinical trial, in 20 sites across Europe and North America.